每经AI快讯，1月20日，港股午间收盘，恒生科技指数跌0.66%，恒生指数跌0.04%。板块方面，客运航 空公司、医疗保健服务板块涨幅靠前；酒店和度假村REIT、生物科技板块跌幅靠前。个股方面，泡泡 玛特涨8.46%，兆易创新涨4.69%，中国东方航空股份涨4.56%，MINIMAX-WP涨4.18%，中国中免涨 4.06%，中国海外发展涨4.0%；药捷安康-B跌9.77%，新世界发展跌10.57%。 ...

Macro Changes - The market's rise at the beginning of 2026 is fundamentally a continuation of the global "easing consensus" from 2025, but three marginal changes are disrupting this trend [3] - The U.S. political cycle is intensifying the clash with monetary policy, as Trump pressures the Federal Reserve to lower interest rates, leading to heightened market expectations for a rate cut [3][7] - The expansion of "shadow banking" in the U.S. has shifted from a hidden concern to a significant variable, with money market funds and private credit rapidly growing, which could amplify liquidity and asset bubbles [4] Policy Dynamics - The Federal Reserve faces three constraints: persistent inflation, political pressure, and the balance between shrinking and expanding its balance sheet [7] - The European Central Bank and other global central banks are signaling potential policy shifts in response to U.S. monetary policy changes, indicating a global interconnectedness in policy decisions [8] Asset Implications - U.S. Treasury yields may steepen if rate cuts occur, but long-term rates could remain suppressed due to fiscal deficits [9] - The U.S. stock market is supported by liquidity expectations, but shadow banking could increase volatility through retail leverage [9] - Gold prices are expected to rise due to declining real interest rates and increased demand for safe-haven assets [9] Investment Shifts - China's "deposit migration" reflects a shift in asset allocation from risk-free to risk-return matching, impacting A-shares, Hong Kong stocks, and the bond market [11] - A-shares are transitioning from "stock game" to "incremental drive," with significant capital moving into equity markets, benefiting high-dividend and growth sectors [11] - Hong Kong stocks are experiencing dual elasticity, attracting both domestic and foreign investments due to improving fundamentals and lower financing costs [12] Conclusion - The global market in 2026 represents a struggle between normalized policy interventions and spontaneous market dynamics, with shadow banking and deposit migration indicating a new era for emerging market assets [13] - Investors should focus on policy-sensitive assets, growth-oriented investments, and safe-haven assets to navigate the evolving landscape [13]

转自：中国质量报 质量换来"信用款" 专利贷来"发展钱" 了解企业困境后，十堰市市场监管局工作人员主动上门，宣讲"鄂质贷"政策——这是一款专门为获得各 级政府质量奖、质量标杆、品牌示范等质量荣誉的企业量身定制的质量融资增信产品，将质量"软实 力"转化为融资"硬通货"。在该局精准对接下，湖北交通银行迅速启动授信审批流程，企业凭借多年积 累的质量信誉，无需额外抵押物，仅用两天时间便顺利获得贷款，解了燃眉之急。 "嘭、嘭、嘭……"1月15日，湖北省十堰市寅云实业有限公司20台框架式拉伸液压机、开式固定台压力 机"火力全开"，该公司的工人在操作台上有序冲压各种汽车车身件，车间内暖意融融、机声隆隆，一派 热火朝天的忙碌景象。 无形的资产，有形的支持。这是十堰市市场监管局创新服务模式、深挖无形资产"富矿"，精准破解企业 融资难题的生动实践。据统计，2025年，该局通过质量、商标、专利等无形资产质押，成功帮助企业实 现融资19.93亿元，为经营主体爬坡过坎、发展壮大输送源源不断的金融活水。 "鄂质贷"精准滴灌实体企业 "没想到，我们多年坚持质量管理的努力，真的换来了真金白银！"谈起不久前到账的230万元"鄂质 贷"，十堰市 ...

Core Insights - The article reviews the evolution of backdoor listings in Hong Kong over the past 40 years, categorizing it into three phases: early exploration, regulatory games, and comprehensive tightening. The traditional "buy shell - inject capital" model ended after the new regulations in 2019 [2][3]. Group 1: Definition and Structure of Backdoor Listings - Backdoor listing is described as a capital activity where a non-listed company acquires control of a listed company (shell company) to achieve indirect public listing by injecting its business and assets [4]. - The transaction process of backdoor listings typically involves two key stages: obtaining control and asset injection and restructuring [4][6]. - The concept of "reverse takeover" (RTO) is clarified as a method where a non-listed company injects assets into a listed shell company to gain control, which is a core regulatory focus in Hong Kong [8][9]. Group 2: Historical Evolution of Backdoor Listings - The first phase (1984-2003) was characterized by strong financing demand and a lack of clear regulatory frameworks, leading to the emergence of backdoor listings as a quicker alternative for mainland companies to access international capital [13][14]. - The second phase (2004-2018) saw increased regulatory scrutiny due to frequent backdoor activities, leading to the introduction of the "bright-line test" in 2004, which established clear thresholds for transactions that would be classified as reverse takeovers [15][16]. - The third phase (2019-present) marked a significant tightening of regulations with the introduction of the "most stringent" new rules aimed at increasing costs and uncertainties associated with backdoor listings, effectively aligning them with IPO standards [17][18][19]. Group 3: Market Changes Post-New Regulations - From 2019 to 2025, the backdoor listing market has undergone structural changes due to high regulatory pressure, global liquidity tightening, and macroeconomic cycles, transforming backdoor listings into high-cost industrial acquisition methods [21]. - The number of transactions classified as reverse takeovers surged from 6 in the first nine months of 2019 to 18 in the following year, with most being terminated due to non-compliance with new regulations [22]. - The value of shell companies has drastically decreased, with prices dropping from 600-650 million HKD to 150-250 million HKD by 2025, reflecting a significant loss of their function as a shortcut to listing [23]. Group 4: New Transaction Forms and Market Dynamics - The introduction of SPACs in 2022 aimed to provide a compliant alternative for backdoor listings, but high regulatory thresholds have limited their effectiveness, resulting in only a few successful cases [24]. - A new approach called "Long-stop Asset Injection" has emerged, where buyers maintain existing businesses for 36 months before conducting substantial operations, shifting the focus from financial speculation to long-term strategic investments [25]. - The intermediary landscape has shifted, with mainland Chinese securities firms gaining prominence in the backdoor and merger advisory sectors, reflecting the changing dynamics of the market [26]. Group 5: Regulatory Enforcement and Market Cleanup - Regulatory practices have intensified, with detailed inquiries for large asset injections and a significant increase in delistings, totaling over 230 companies from 2019 to 2025, indicating a strong push to eliminate "zombie stocks" [27].

1月16日，华大基因跌6.85%，成交额11.68亿元。两融数据显示，当日华大基因获融资买入额1.07亿 元，融资偿还2.42亿元，融资净买入-1.36亿元。截至1月16日，华大基因融资融券余额合计11.31亿元。 融资方面，华大基因当日融资买入1.07亿元。当前融资余额11.27亿元，占流通市值的5.09%，融资余额 超过近一年90%分位水平，处于高位。 融券方面，华大基因1月16日融券偿还3.37万股，融券卖出3300.00股，按当日收盘价计算，卖出金额 17.49万元；融券余量6.05万股，融券余额320.65万元，低于近一年30%分位水平，处于低位。 资料显示，深圳华大基因股份有限公司位于广东省深圳市盐田区梅沙街道云华路9号华大时空中心B区8 层，成立日期2010年7月9日，上市日期2017年7月14日，公司主营业务涉及通过基因检测、质谱检测、 生物信息分析等多组学大数据技术手段,为科研机构、企事业单位、医疗机构、社会卫生组织等提供研 究服务和精准医学检测综合解决方案。主营业务收入构成为：精准医学检测综合解决方案42.67%，生 育健康基础研究和临床应用服务26.12%，多组学大数据服务与合成业务17 ...

Group 1 - The company has established a flexible design concept for its pilot testing facility, allowing for rapid adjustments in process modules, which significantly enhances research and development efficiency [1] - Since its opening in April 2024, the pilot testing facility has attracted numerous new technologies and products for verification, making it one of the most comprehensive pilot bases in the field of synthetic biology in China [1][2] - The company operates under a "headquarters + base" model, with a strong focus on fermentation and enzyme-catalyzed products, providing a full chain of services from pilot testing to contract research [2] Group 2 - The pilot platform has been recognized as a "five-star" service level by the Ministry of Industry and Information Technology, placing the company among the top in the national biomanufacturing sector [2] - The company has successfully connected with 42 technology achievements and completed 22 pilot projects, including collaborations with over 30 universities and research institutions [3] - The city of Hebi has developed 33 pilot testing bases, creating a robust and active innovation ecosystem that links laboratories with the industrial chain [4]

Core Viewpoint - Sifang Optoelectronics has signed a strategic investment agreement with Suzhou Changhe Biotechnology, acquiring a 57.14% stake in the company, aiming to expand into the high-end bio-safety detection instrument sector [1] Group 1: Strategic Investment - The investment was made using Sifang Optoelectronics' own funds through the transfer of equity and capital increase [1] - This strategic integration will allow both companies to deeply merge in product technology development, operational production, and sales channels [1] Group 2: Market Expansion - Sifang Optoelectronics plans to leverage its core component advantages in the sensor field to develop low-cost bio-safety sensors [1] - The new bio-safety sensors are intended for mass application in household appliances, automobiles, and buildings [1]

Group 1 - The core viewpoint of the article is the release of the first "2025 Hurun China Unicorn Graduation List," which identifies 796 companies valued over $1 billion that have gone public since 2000, with 18 companies from Chengdu making the list, ranking seventh nationally [1] Group 2 - The 18 Chengdu companies listed include: Xinyi Sheng, Kelun Botai Biotech, AVIC Drone, Chengdu Huamei, Jiachitech, Dekang Agriculture, Huatu Shanding, Chabaidao, Leidian Weili, Tianwei Food, Qiaoyuan Co., Kangnuo Ya, Zhenxin Technology, Fusenmei, Bomei, XGIMI Technology, Hongqi Chain, and Tianli International Holdings [1] - The listed unicorns are distributed across 126 cities in China, with a total value of 24 trillion yuan, and an average age of 19 years, which is 9 years older than those on the 2025 Hurun Global Unicorn List [1] Group 3 - The top five industries with the most companies on the list are semiconductors, industrial equipment, biotechnology, new energy, and software services, accounting for 46% of the total [1] - The highest valued industries among the listed companies are semiconductors, new energy, industrial equipment, consumer electronics, and biotechnology [1]

Core Insights - The event "Walking into Chuxiong High-tech Zone" organized by Chuxiong High-tech Zone aims to bridge top university intellectual resources with local industrial development, promoting substantial and institutional cooperation [1][3] - A delegation of 20 distinguished alumni from various fields, including talent development research, chip design, and environmental technology, participated in discussions on collaboration and development [1][3] Group 1 - The delegation conducted on-site visits to representative companies such as Yunnan Yunla Biological Technology, Chuxiong Laoboyuntang Pharmaceutical, Chuxiong Chuanzi Electronic Materials, and Yunnan Sanen New Energy Materials, gaining a comprehensive understanding of the high-tech zone's robust industrial foundation, active innovation ecosystem, and favorable business environment [3] - During the afternoon seminar, attendees watched promotional videos about Chuxiong City and the high-tech zone, learning about the region's natural and cultural endowments, economic and social development achievements, and the high-tech zone's advantages in industrial planning, innovation ecosystem, and policy support [3] - Chuxiong High-tech Zone is currently in a critical phase aiming for a trillion-level industrial target, with a pressing need for technological support and talent assurance, seeking to leverage Tsinghua alumni to integrate cutting-edge innovations with local industries for high-quality regional development [3] Group 2 - A memorandum of understanding on industrial talent cooperation was signed between Chuxiong High-tech Zone and the Tsinghua University Alumni Association, outlining six areas of deep cooperation [4] - The signing of the memorandum marks a significant step in the collaboration between Chuxiong High-tech Zone and the Tsinghua University Alumni Association, laying a solid foundation for the advancement of subsequent specific cooperation projects [4]

Core Viewpoint - Doning Biotechnology has submitted an application for listing on the Hong Kong Stock Exchange, aiming to become a mainboard listed company, with Morgan Stanley and Huatai International as joint sponsors [1] Company Overview - Established in 2005, Doning Biotechnology is rooted in the life sciences industry, providing comprehensive solutions for the development and commercialization of biopharmaceutical products [1] - The company operates two main business lines: 1. Bioprocess Solutions, offering a wide range of products including reagents, consumables, and equipment that cover all major steps of bioprocessing 2. Laboratory Products and Services, providing products for laboratory R&D and bioprocess solutions, including technical development, testing, and validation services [1] Financial Performance - In the first nine months of the previous year, the company reported revenue of 658 million yuan, representing a year-on-year increase of 19.39% - The profit attributable to shareholders was 21.604 million yuan [1]